Table 2.
Identified metabolites associated with achieving sustained drug-free remission in the three strategy arms
| Tocilizumab plus methotrexate | SMD | p value | Tocilizumab | SMD | p value | Methotrexate | SMD | p value |
|---|---|---|---|---|---|---|---|---|
| Histamine▼ | − 1.75 | 0.002 | PGE2▲ | 0.93 | 0.019 | L-Lysine▲ | 0.95 | 0.032 |
| 9,12,13-TriHOME▲ | 0.52 | 0.002 | L-Pipecolic acid▲ | 0.42 | 0.026 | L-Proline▲ | 0.98 | 0.040 |
| Spha c18:0▼ | − 1.34 | 0.007 | 8,9-DiHETrE▲ | 0.81 | 0.026 | 3-Methylhistidine▼ | − 1.05 | 0.06 |
| 9,10,13-TriHOME▲ | 1.05 | 0.010 | 5,6-DiHETrE▲ | 0.79 | 0.034 | Anserine▲ | 0.73 | 0.06 |
| LPA c20:3▼ | − 1.29 | 0.012 | 8-iso-PGE2▲ | 0.89 | 0.034 | 19,20-DiHDPA▼ | − 1.03 | 0.06 |
| Sph c18:1▼ | − 0.83 | 0.012 | 20-carboxy-LTB4▲ | 0.50 | 0.035 | 5-Hydroxy-L-tryptophan▼ | − 0.40 | 0.08 |
| LPA c18:1▼ | − 0.93 | 0.033 | Cystathionine▼ | − 0.96 | 0.052 | L-Arginine▲ | 0.98 | 0.08 |
| L-Methionine sulfoxide▲ | 1.01 | 0.033 | Norepinephrine▼ | − 0.39 | 0.052 | LPA c18:3 (w3/w6)▲ | 0.80 | 0.08 |
| 8,9-DiHETrE▼ | − 0.94 | 0.042 | 3-Methylhistidine▼ | − 0.61 | 0.07 | 12,13-DiHODE▼ | − 0.60 | 0.10 |
| LPA c16:0▼ | − 0.81 | 0.052 | TXB2▲ | 0.82 | 0.08 | 14,15-DiHETE▼ | − 0.96 | 0.10 |
| NO2-OA▼ | − 0.98 | 0.052 | 8-iso-PGA2▲ | 0.58 | 0.08 | cLPA c16:0▲ | 0.71 | 0.10 |
| L-Kynurenine▼ | − 1.03 | 0.06 | aLPA c16:1▼ | − 0.24 | 0.08 | PAF c16:0▲ | 0.87 | 0.10 |
| LPA c22:4▼ | − 1.03 | 0.06 | Homocysteine▼ | − 0.78 | 0.09 | |||
| LPA c20:4▼ | − 0.97 | 0.06 | ||||||
| Methyldopa▼ | − 0.88 | 0.08 | ||||||
| PGD2▲ | 0.02 | 0.08 | ||||||
| LPA c16:1▼ | − 0.84 | 0.08 | ||||||
| Hydroxylysine▲ | 0.66 | 0.10 | ||||||
| PGF3a▲ | 0.07 | 0.10 | ||||||
| 12,13-DiHODE▲ | 0.85 | 0.10 |
▲On average, higher concentration in the sDFR group vs controls; ▼on average, lower concentration in the sDFR group vs controls. sDFR sustained drug-free remission, SDM standardized mean difference